FindTrial
Sign In

Short-Time Second Generation Tyrosine Kinase inhibitors Combined With Allogeneic Stem Cell Transplantation for Patients with Imatinib-refractory CML

Short-Time Second Generation Tyrosine Kinase inhibitors Combined with by Allogeneic Stem Cell Transplantation for Patients with Imatinib-refractory CML

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-12002856
Enrollment
Unknown
Registered
2012-12-25
Start date
2012-12-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic myeloid leukemia

Interventions

2nd TKI combined with SCT:short-time second-generation tyrosine kinase inhibitors (TKI) used before and after allo-SCT

Sponsors

Bone marrow transplant center, 1st Affiliated Hospital, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. gave informed consent; 2. age less than 60 years; 3. diagnosed with CML, as confirmed by the presence of the Philadelphia (Ph) chromosome or the BCR-ABL fusion gene; 4. imatinib treatment failure.

Exclusion criteria

Exclusion criteria: 1. severe irreversible comorbidity, such as renal, hepatic, pulmonary, or cardiac disease; 2. development of grade >=3 adverse events during 2nd TKIs therapy; 3. pregnancy or lactation; 4. has T315I BCR-ABL kinase domain mutation.

Design outcomes

Primary

MeasureTime frame
3- year Overall Survival;—

Secondary

MeasureTime frame
3-year disease free survival;engraftment rate;3- year cumulative relapse rate;Response rate to 2nd TKI;—

Countries

China

Contacts

Public ContactHe Huang
hehuangyu@126.com+86 13605714822

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026